GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Shares Outstanding (EOP)

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Shares Outstanding (EOP) : 1,115 Mil (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Shenzhenlubris Pharmaceuticals Co's shares outstanding for the quarter that ended in Dec. 2024 was 1,115 Mil.

Shenzhenlubris Pharmaceuticals Co's quarterly shares outstanding stayed the same from Sep. 2024 (1,115 Mil) to Dec. 2024 (1,115 Mil).

Shenzhenlubris Pharmaceuticals Co's annual shares outstanding stayed the same from Dec. 2023 (1,115 Mil) to Dec. 2024 (1,115 Mil).


Shenzhenlubris Pharmaceuticals Co Shares Outstanding (EOP) Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Shares Outstanding (EOP) Chart

Shenzhenlubris Pharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,046.02 1,114.82 1,114.82 1,114.82 1,114.82

Shenzhenlubris Pharmaceuticals Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,114.82 1,114.82 1,114.82 1,114.82 1,114.82

Competitive Comparison of Shenzhenlubris Pharmaceuticals Co's Shares Outstanding (EOP)

For the Medical Instruments & Supplies subindustry, Shenzhenlubris Pharmaceuticals Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhenlubris Pharmaceuticals Co's Shares Outstanding (EOP) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's Shares Outstanding (EOP) falls into.


;
;

Shenzhenlubris Pharmaceuticals Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Shenzhenlubris Pharmaceuticals Co  (SZSE:002294) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Shenzhenlubris Pharmaceuticals Co Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhenlubris Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 6009 Shennan Road, 37th Floor, Main Building, Chegongmiao Lvjing Plaza, Futian District, Guangdong, Shenzhen, CHN, 518040
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
Executives
Yan Jie Directors, executives
Yang Jian Feng Secretary, Director
Zhao Song Ping Executives
Liu Jun Executives
Li Ai Zhen Supervisors
Chen Ping Executives
Ye Cheng Hai Director
Lu Feng Executives, directors
Chen Qiong Xing Supervisors
Li Ying Hui Supervisors
Pan Ling Man Independent director
Zhang Zhong Xing Executives

Shenzhenlubris Pharmaceuticals Co Headlines

No Headlines